ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced that its clinical trial technology solutions have been shortlisted for two Informa Clinical and Research Excellence (CARE) Awards.
Informa, a leading business intelligence and academic publishing company, conducts the annual CARE Awards to showcase significant accomplishments and highlight innovation across the industry. ERT is being recognized in the category of Best Sponsor-focused Clinical Development for its Centralized Clinical Trial Analytics Solution and in the category of Best Patient-focused Clinical Development for its novel Voice Assistance Data Capture solution.
“Our panel of independent experts carefully judged all entries to produce a shortlist that displays the industry’s wealth of innovation, unwavering commitment and passion to make human lives better,” said Karen Currie, Executive Director, Editorial, Citeline, Informa. “We received a record-setting number of entries for this year’s program and are pleased to recognize ERT as a finalist for these key award categories.”
ERT’s Centralized Clinical Trial Analytics Solution helps sponsors and CROs achieve a new level of day-to-day trial management efficiency across study teams with real-time visibility into performance and risk indicators. By harmonizing the people, processes, and technologies across a trial’s multiple service providers, information silos and data sources, the system delivers real-time data analytics that help sponsors and CROs proactively mitigate risk, while eliminating hundreds of hours typically spent on manual data entry, spreadsheets and trackers.
Developed in collaboration with Orbita, a healthcare software provider, ERT’s Voice Assistant Data Capture Solution improves patient engagement by enabling clinical trial participants to complete daily assessment surveys, report vital statistics measurements, ask questions, receive training and report health concerns via voice recognition technology. Additional applications are under development.
“ERT is committed to exploring and developing solutions that help the biopharmaceutical industry bring new treatments to the patients who need them quickly, and with confidence,” said James Corrigan, President and CEO, ERT. “We’re honored to be recognized for enabling sponsors to simplify patient participation and for helping them avoid costly trial delays by spotting risks before they become problems during clinical development.”